E-LIB Suche - Ergebnisse für: Rieder, F

1

P545 Long-term efficacy of ozanimod up to 3 years in patien..:

Schreiber, S W ; Feagan, B G ; Sands, B E...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1074-i1075 , 2024

Link: https://doi.org/10.1093/..

2

P144 Modulation of Immunometabolism via NLRX1 or PLXDC2: No..:

Danese, S ; Colombel, J F ; Rieder, F...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i443-i445 , 2024

Link: https://doi.org/10.1093/..

3

P117 Transglutaminase 2 is elevated in Crohn's disease asso..:

Chandra, J ; Czarnecki, D ; Mukherjee, P K...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i405-i405 , 2024

Link: https://doi.org/10.1093/..

4

OC.13.2: EARLY HISTO-ENDOSCOPIC RESPONSE PREDICTS CLINICAL ..:

Magro, F. ; Pai, R.K. ; Kobayashi, T....
Digestive and Liver Disease. 56 (2024) - p. S193 , 2024

Link: https://doi.org/10.1016/..

5

OP22 Topical Sphingosine-1-Phosphate (S1P) Receptor 1 Modul..:

Wang, J ; West, G ; Lin, S...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i40-i40 , 2024

Link: https://doi.org/10.1093/..

6

DOP78 Efficacy of ozanimod by patient response trajectory s..:

Schreiber, S W ; Feagan, B G ; Sands, B E...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i217-i218 , 2024

Link: https://doi.org/10.1093/..

7

OP25 Dual activation of GCGR/GLP1R signaling ameliorates in..:

Liu, H ; Hong, Y ; Wang, X...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i44-i46 , 2024

Link: https://doi.org/10.1093/..

8

DOP12 Validation of radiomics features on MR enterography c..:

Sleiman, J ; Chirra, P ; Gandhi, N...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i73-i73 , 2023

Link: https://doi.org/10.1093/..

9

OP38 Modulation of the septin cytoskeleton ameliorates inte..:

Naydenov, N ; Le, T H N ; Lechuga Villarauz, S...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i54-i55 , 2023

Link: https://doi.org/10.1093/..

10

P235 Patients with inflammatory ileal pouch anal anastomosi..:

Qazi, T ; Ottichilo, R ; Grove, D...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i388-i389 , 2023

Link: https://doi.org/10.1093/..

11

P242 Universal exclusion of patients with Permanent Ileosto..:

Vuyyuru, S ; Solitano, V ; Nguyen, T..
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i394-i395 , 2023

Link: https://doi.org/10.1093/..

12

P577 A Phase 1b Study to Evaluate Safety, Tolerability, Pha..:

Peyrin-Biroulet, L ; Danese, S ; Colombel, J F...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i705-i706 , 2023

Link: https://doi.org/10.1093/..

13

P420 Safety & feasibility of targeted mesenteric approaches..:

Holubar, S ; Cohen, B ; Uchino, T...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i549-i550 , 2023

Link: https://doi.org/10.1093/..

14

P093 Creeping fat-derived long chain free fatty acids drive..:

Le, T H N ; Mao, R ; Liu, W...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i255-i256 , 2023

Link: https://doi.org/10.1093/..

15

P270 A global consensus on the definitions, diagnosis and m..:

Bettenworth, D ; Baker, M E ; Bemelmann, W...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i418-i420 , 2023

Link: https://doi.org/10.1093/..